

## FOI Request re Number of Patients Treated

Please detail the number of Oncology patients treated<sup>1</sup> (either as a monotherapy or combination therapy) by your Trust with the stated therapies, during the 12 months **January 2018 to December 2018** inclusive.

	Total Number of Patients Treated (regardless of Tumour Type)	Total Number of Patients Treated:				
		Head & Neck Cancer	Adjuvant Melanoma	Metastatic Melanoma	Non-Small Cell Lung Cancer (NSCLC)	Renal Cell Carcinoma (RCC)
Pembrolizumab (Keytruda)	40	*	0	10	24	*
Nivolumab (Opdivo)	33	*	0	13	*	14
Ipilimumab (Yervoy)	*	*	0	0	0	0
Nivolumab & Ipilimumab	13	*	0	13	0	0
Dabrafenib (Tafinlar)	*	*	0	*	0	0
Cabozantinib (Cabometyx)	*	*	0	0	0	0
Sunitinib (Sutent)	*	*	0	0	0	*
Pazopanib (Votrient)	*	*	0	0	0	*
Axitinib (Inlyta)	*	*	0	0	0	0
Atezolizumab (Tecentriq)	25	*	0	0	24	0
Sorafenib (Nexavar)	*	*	0	0	0	0
Tivozanib (Fotivda)	*	*	0	0	0	0
Cetuximab (Erbix)	*	*	0	0	0	0
Everolimus (Afinitor)	14	*	0	0	0	*
Vemurafenib (Zelboraf)	*	*	0	0	0	0
Total Number Treated (all treatments)	132	**	0	**	**	20

<sup>1</sup> Please indicate the number of patients (excluding clinical trial patients) treated (any patients treated, not only those for whom treatment with the therapy was initiated) with the stated active anti-cancer drug treatment(s).